News | September 05, 2024
Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Phase 3 study results will form the basis for future discussions with global regulatory authorities
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Subscribe To Our Newsletter & Stay Updated
